https://www.pharmaradar360.com/article/62f59d59ddb2fd1bPharma Surgeen2026-06-09T10:41:05.000ZGuidance: AI Airlock Simulation Workshopshttps://www.pharmaradar360.com/article/e042e8b71b7377dePharma Surgeen2026-06-09T10:37:42.000ZGuidance: AI Airlock Sandbox Phase 2 Programme Reporthttps://www.pharmaradar360.com/article/6204144f8c50e3b7Pharma Surgeen2026-06-09T10:08:24.000ZΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 31 ΜΑΪΟΥhttps://www.pharmaradar360.com/article/884157d5592502edPharma Surgeen2026-06-09T09:59:21.000Zο ΕΟΦ είναι μέλος του Ευρωπαϊκού Δικτύου Ρυθμιστικών Αρχών Φαρμάκων (EMRN)https://www.pharmaradar360.com/article/cfc2b16fbc16b9d6Pharma Surgeen2026-06-09T07:46:00.000ZThe guidance on digital and decentralised clinical trials (DCT) has been updatedhttps://www.pharmaradar360.com/article/58e5f910a0ab273aPharma Surgeen2026-06-09T07:39:41.000ZRA Committee Townhall – How Agentic AI is Redefining Regulatory Excellencehttps://www.pharmaradar360.com/article/cb41d961f6a7a91cPharma Surgeen2026-06-09T06:00:08.000ZUN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)https://www.pharmaradar360.com/article/bfcb61eac3282003Pharma Surgeen2026-06-09T02:00:00.000ZPharmac to fund medicines used by ambulance providershttps://www.pharmaradar360.com/article/de1cd4223d7b4ba2Pharma Surgeen2026-06-09T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/5b945f6bb3137cbbPharma Surgeen2026-06-09T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/0e126fd9215b56cePharma Surgeen2026-06-09T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/d16d0abf0ae297edPharma Surgeen2026-06-09T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/9f991bda34984727Pharma Surgeen2026-06-09T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/962d9fa9d7dd472dPharma Surgeen2026-06-09T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/84563d1cd0ff04abPharma Surgeen2026-06-09T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/c658c7671c8f0311Pharma Surgeen2026-06-09T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/abeb351f0da8bc51Pharma Surgeen2026-06-09T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/bccec93bc17beb39Pharma Surgeen2026-06-09T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/2bb4a43449cd2136Pharma Surgeen2026-06-09T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/63b6fd5d13523fabPharma Surgeen2026-06-09T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/aba0d7dc2cadb4a2Pharma Surgeen2026-06-09T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/097414eacd628388Pharma Surgeen2026-06-09T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/49971b9dd9fe51c3Pharma Surgeen2026-06-08T20:39:58.000ZGilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatmenthttps://www.pharmaradar360.com/article/2d8fc949202d0f77Pharma Surgeen2026-06-08T20:30:00.000ZMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Studyhttps://www.pharmaradar360.com/article/8f0559512800821aPharma Surgeen2026-06-08T18:30:00.000ZLilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialshttps://www.pharmaradar360.com/article/e947f2438a0dac0bPharma Surgeen2026-06-08T14:50:02.000ZPharmaceutical industry’s response to the Ebola Bundibugyo virus disease outbreakhttps://www.pharmaradar360.com/article/a59e9e084e383264Pharma Surgeen2026-06-08T14:42:29.000ZCrise au Moyen-Orient, un impact sur les prix de production des médicamentshttps://www.pharmaradar360.com/article/d7ddbf65e48c850bPharma Surgeen2026-06-08T14:41:08.000ZU.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT AFFIRMS VICTORY FOR CORMEDIX THERAPEUTICS IN MINOCIN® PATENT LITIGATIONhttps://www.pharmaradar360.com/article/300c34f00549b3cePharma Surgeen2026-06-08T13:37:42.000ZCorporate report: Advertising investigations: May 2026https://www.pharmaradar360.com/article/0f83a94241cc5663Pharma Surgeen2026-06-08T13:08:16.000ZPharmaceutical industry’s response to the Ebola Bundibugyo virus disease outbreakhttps://www.pharmaradar360.com/article/b06cc76eb8a1d6faPharma Surgeen2026-06-08T13:00:00.000ZChina’s NMPA clears Hansoh’s HS-10541 for clinichttps://www.pharmaradar360.com/article/75df1fe0b1af974aPharma Surgeen2026-06-08T12:59:29.000ZNAFDAC Joins Federal Ministry of Health & Social Welfare, National Food Safety Management Committee and the rest of the world in celebrating World Food Safety Dayhttps://www.pharmaradar360.com/article/720962b226af3accPharma Surgeen2026-06-08T12:59:08.000ZeXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrantshttps://www.pharmaradar360.com/article/f4b4b249cdaf52b8Pharma Surgeen2026-06-08T12:27:39.000ZClinical trials for medicines: modifying a clinical trial approvalhttps://www.pharmaradar360.com/article/11d15d3125b04d8bPharma Surgeen2026-06-08T12:00:00.000ZAbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026https://www.pharmaradar360.com/article/bf055398feae6589Pharma Surgeen2026-06-08T11:58:31.000ZIncorporación al MERCOSUR sobre “ MATERIALES, ENVASES Y EQUIPAMIENTOS CELULÓSICOS DESTINADOS A ESTAR EN CONTACTO CON ALIMENTOS”https://www.pharmaradar360.com/article/2d04f6fac5fd7deaPharma Surgeen2026-06-08T11:53:07.000ZIncorporación de la actualización MERCOSUR sobre el uso de almidones en quesos de muy alta humedadhttps://www.pharmaradar360.com/article/2bfe0e12c668ad73Pharma Surgeen2026-06-08T11:46:33.000ZIncorporación de la actualización MERCOSUR sobre límites de arsénico en arroz y sus derivadoshttps://www.pharmaradar360.com/article/7ac93c655025c419Pharma Surgeen2026-06-08T11:34:56.000ZTraining on the use of the new version of the Estonian Medical Devices and Appliances Databasehttps://www.pharmaradar360.com/article/f8d63ed9a914ab9fPharma Surgeen2026-06-08T11:26:22.000ZField Safety Notices: 1-5 June 2026https://www.pharmaradar360.com/article/13df25ac7537613dPharma Surgeen2026-06-08T10:59:00.000ZMariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Diseasehttps://www.pharmaradar360.com/article/afe16e16a0a7f51ePharma Surgeen2026-06-08T10:46:52.000ZLa AEMPS informa de un riesgo de suspensión de la administración de insulina en determinadas bombas Minimed 780Ghttps://www.pharmaradar360.com/article/0a3af39ee32fb8cfPharma Surgeen2026-06-08T10:02:33.000ZClass 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28https://www.pharmaradar360.com/article/80d956a3ea88da5fPharma Surgeen2026-06-08T09:17:00.000ZFind product information about medicineshttps://www.pharmaradar360.com/article/0075ab19af93c24ePharma Surgeen2026-06-08T08:33:02.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/d86c8fdc2d0efd4ePharma Surgeen2026-06-08T08:09:06.000ZBiopharma deals thrive on creativity, from structure through to execution